#Coronavirus Testing Kits Market | Explore Tumblr posts and blogs

homehealthcarehub101 · 1 year ago

Text

Home PCR Tests: A Closer Look at the PCR Test At Home Dubai Option

The COVID-19 pandemic sparked major growth in the development and usage of diagnostic and antibody tests that patients can self-administer from home. Home PCR tests in particular enable private, convenient detection of active coronavirus infections. For those wondering whether accurate PCR Test At Home Dubai kits are available, exploring the leading options provides helpful guidance.

How Do Home PCR Tests for COVID-19 Work?

The PCR (polymerase chain reaction) technique is the gold standard for directly detecting the presence of the COVID-19 virus from respiratory samples. Home PCR test kits allow patients to collect their own nasal or saliva samples and perform the PCR assay without visiting a clinic.

PCR tests work by identifying the specific genetic material of the COVID-19 virus. Users collect a sample, mix it with chemical reagents, and insert the solution into the test kit for analysis. Results are displayed indicating whether viral genetic material was detected based on any color change reaction on the test strips.

Kits include step-by-step instructions to ensure patients perform the easy, quick tests properly using non-invasive nasal swabs or saliva collection. Many provide results within 10-30 minutes.

Here is a video from MedCram Youtube Channel about At Home Rapid COVID 19 Tests and False Positives (Coronavirus Antigen Tests). Watch the video

youtube

Benefits of At-Home PCR Testing

Here are some of the major advantages of having access to accurate home PCR tests for COVID-19:

Convenience: Test from the privacy of your residence without traveling to clinics.

Speed: Get results rapidly within minutes rather than waiting days for lab tests.

Self-Administered: Users can collect their own sample comfortably rather than relying on technicians.

Affordability: Individual kits are very competitively priced.

Detection Reliability: PCR technology directly identifies viral presence with high accuracy.

Ease of Use: Tests have simple, straightforward instructions for patients of all ages.

Infection Verification: Confirms active infections unlike antibody tests.

Having the option to privately, quickly, and accurately test for possible COVID-19 infections at home provides significant peace of mind during the pandemic.

How Reliable Are Home PCR Tests?

Many people reasonably wonder whether DIY home PCR test kits can match the reliability of lab-based PCR tests. The good news is that leading home PCR kits on the market have very high accuracy.

Most kits have published sensitivity and specificity above 90% when compared to lab PCR tests. High quality home tests analyze samples using comparable PCR methodology and match labs in detecting positives and negatives.

Furthermore, unlike Rapid PCR Test At Home kits some vendors offer, full home PCR tests analyze the sample through many amplification cycles to maximize accuracy. With good sampling collection, top home PCR kits offer laboratory-grade results conveniently at home.

Leading Home PCR Test Kit Options

For those exploring PCR Test At Home Dubai choices, here are some of the top-rated home PCR kits to consider:

Cue Health PCR Test: Cue offers an FDA-authorized home PCR test delivering highly accurate results in 20 minutes with nasal swab samples.

Lucira Check It PCR Test: This is a single-use PCR kit with 98% validated accuracy that provides molecular-level detection from nasal samples in 30 minutes or less.

Ellume COVID-19 Home Test: This over-the-counter home kit uses a mid-turbinate nasal sample and provides an amplified PCR digital reading of positive or negative in 15 minutes on a connected analyzer.

Pixel by LabCorp PCR Test: Pixel is a monitored at-home nasal PCR test analyzed through LabCorp with over 98% accuracy returning results within 1-2 days.

Doximity's Covid-19 PCR Test: Doximity partners with qualified labs for monitored video-observed PCR testing with 97%+ accuracy and results in 24 hours.

All these options allow for convenient, accurate at-home COVID-19 testing using PCR with trusted partners. Kits can be purchased online and shipped directly to your home in Dubai.

When Are Home PCR Tests Recommended?

The CDC recommends utilizing home PCR tests in situations such as:

If you have any symptoms of COVID-19. Home testing allows quick confirmation.

After exposure events to quickly check for possible infection.

Before visiting individuals at higher risk for severe illness.

Before travel or group events for added assurance.

For frequent screening in schools or workplaces.

Even fully vaccinated individuals should test if they experience COVID-like symptoms or have a known exposure. Home PCR tests make quick detection fast and easy.

Home PCR Tests Offer Accuracy and Convenience

High quality Home PCR Tests have become an important tool in the fight against COVID by making reliable diagnostic testing accessible outside of clinics. There are excellent PCR Test At Home Dubai options available matching the standards of lab PCR sensitivity and specificity. Home PCR kits allow people to conveniently and confidently check themselves for possible COVID-19 infections from the privacy of home. As the technology continues advancing, home collection PCR will likely take on an increasingly vital role supporting public health and safety.

#home health services #pcr test #covid testing #Youtube

2 notes · View notes

pranay-234 · 1 year ago

Text

Physiological Saline Market Strategic Imperatives for Success and Rising Demand Till 2032

Physiological saline, often called normal saline, is a simple yet essential component of healthcare worldwide. It's not only a fundamental part of medical practice but also a critical player in various industries. In this article, we delve into the trends and growth prospects of the global physiological saline market.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐎𝐟 𝐑𝐞𝐩𝐨𝐫𝐭 : https://www.alliedmarketresearch.com/request-toc-and-sample/11297

The COVID-19 Pandemic: Impact and Resilience

The COVID-19 pandemic has unfolded as an unprecedented crisis, impacting humanity on multiple fronts. From a humanitarian perspective, it has tested the resilience of communities, individuals, and healthcare systems worldwide. Simultaneously, the economic ramifications of the pandemic have been substantial, causing financial strain on businesses and nations. In this article, we will delve into the multifaceted effects of the pandemic, the response of healthcare organizations, and the resilience of critical medical supplies such as physiological saline.

A Dual Crisis: Humanitarian and Economic

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has been a dual crisis, straining both the healthcare sector and the global economy. Industry closures and lockdowns, with people asked to stay in their homes, have taken a toll on economic growth and financial stability.

Human Toll and Healthcare Response

Globally, over 4 million people have been affected by COVID-19, with more than 300,000 lives lost to the virus. Healthcare organizations have been operating in battle mode, responding to the surge in COVID-19 patients. This response has included sourcing rapid diagnostic kits and ensuring an adequate supply of personal protective equipment (PPE) for frontline workers.

Impact on Healthcare Segments

One unintended consequence of the intense focus on COVID-19 has been the diversion of medical resources and attention away from other critical healthcare segments. This has, at times, led to negligence in addressing non-COVID medical conditions, with potential negative consequences.

𝐏𝐫𝐞-𝐛𝐨𝐨𝐤 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐍𝐨𝐰 : https://www.alliedmarketresearch.com/physiological-saline-market/purchase-options

The Resilience of Physiological Saline

In the midst of this crisis, physiological saline, one of the most basic and crucial medical solutions, continues to play a vital role in the healthcare system. The demand for saline solutions remains steadfast, underlining their indispensable nature.

The Ubiquitous Role of Physiological Saline

Physiological saline is a sterile solution containing 0.9% sodium chloride in water. It closely mimics the salt concentration of our bodily fluids, making it compatible with the human body. Here are the key applications that showcase its versatility:

Medical Marvel: In the medical field, physiological saline is indispensable. It's used for wound cleaning, intravenous therapy, inhalation treatments, and as a diluent for medications. Its importance became even more evident during the COVID-19 pandemic when it was used for reconstituting vaccines and in testing procedures.

Pharmaceutical Powerhouse: The pharmaceutical industry relies on physiological saline as a base solution for drug formulation. It ensures that medications can be administered safely and effectively.

Research Realm: Physiological saline is a fundamental component in laboratories. It serves as a control solution and is used in various biological and chemical experiments.

Beauty and Beyond: Beyond the medical and pharmaceutical sectors, it has found its way into the beauty industry as well, where it is used for cosmetic purposes.

Emerging Trends in the Physiological Saline Market

Increased Demand for Sterile Solutions: With the emphasis on infection control in healthcare, the demand for sterile solutions, including physiological saline, is on the rise.

Packaging Innovation: Trends in eco-friendly and easy-to-use packaging are making their mark on the market. These innovations aim to improve convenience and sustainability.

Global Health Initiatives: As access to basic healthcare expands in developing countries, the demand for essential medical supplies, including physiological saline, is increasing.

Customized Saline Solutions: Tailoring saline solutions for specific applications, such as wound care and ophthalmology, is an emerging trend that enhances patient care.

𝐈𝐧𝐭𝐞𝐫𝐞𝐬𝐭𝐞𝐝 𝐭𝐨 𝐏𝐫𝐨𝐜𝐮𝐫𝐞 𝐭𝐡𝐞 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭? 𝐈𝐧𝐪𝐮𝐢𝐫𝐞 𝐁𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠 : https://www.alliedmarketresearch.com/purchase-enquiry/11297

Growth Prospects

The global physiological saline market is poised for steady growth. As healthcare and pharmaceutical industries continue to expand, so does the demand for this essential solution. The market's future holds significant promise, driven by the ever-increasing focus on patient safety and advancements in healthcare practices.

In conclusion, physiological saline might seem simple, but its impact on healthcare and various industries is profound. The trends and growth prospects signal a bright future for this unassuming yet critical solution. As healthcare evolves, physiological saline will remain a steadfast and vital component, ensuring patient well-being and safety worldwide.

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

0 notes

kritikapatil · 1 year ago

Text

Coronavirus Diagnostics Market to Scale New Heights as Market Players Focus on Innovations 2022 – 2027

Latest added Coronavirus Diagnostics Market research study by AMA Research offers detailed outlook and elaborates market review till 2027. The market Study is segmented by key regions that are accelerating the marketization. At present, the market players are strategizing and overcoming challenges of current scenario; some of the key players in the study are

F. Hoffmann-La Roche AG (Switzerland)

Bio-Rad Laboratories Inc. (United States)

Beckman Coulter Inc. (United States)

Becton, Dickinson, and Company (United States)

Lonza Group AG (Switzerland)

Hologic, Inc. (United States)

QIAGEN (Germany)

GlaxoSmithKline Biologicals SA (Belgium)

Abbott Laboratories (United States)

Perkin Elmer, Inc. (United States)

Neuberg Diagnostics (India)

1drop Inc. (Switzerland)

Veredus Laboratories (Hong Kong)

ADT Biotech (Malaysia)

Quest Diagnostics (United States)

LabCorp (United States)

altona Diagnostics GmbH (Germany)

bioMÃ©rieux SA (France)

Mylab Discovery Solutions Pvt Ltd. (India)

Covid-19 is an infectious disease caused by a newly discovered coronavirus. The name Covid-19 represents the virus's membership of the coronavirus family, with its first human interaction noted in 2019. Coronavirus is the term coined for the family of viruses that are transmitted between animals and humans. Hence they are also known as zoonotic viruses. In addition, the virus outbreak was confirmed on March 27, 2020, on six continents and in more than 197 countries. According to the World Health Organization (WHO), fever, fatigue and dry cough are common symptoms of Covid-19 infection. Other symptoms of the disease include shortness of breath, sore throat, pain, and diarrhea in some cases, as well as nausea or a runny nose. In addition, this infection can spread from one person to another through droplets of saliva, or it can leak out of the nose when an infected person coughs or sneezes. The time from a person's exposure to Covid-19 to the onset of symptoms is generally between two and fourteen days, with an average of five days. The current status of lead COVID testing is toward increasing capacity but mixed accuracy. For efficient and accurate COVID-19 diagnosis, doctors need a portable or on-site diagnostic test to be able to manage patients in real-time in the shortest possible time. This has encouraged the introduction of point-of-care (POC) tests for diagnosis, the primary aim of which is to cut test times from hours to minutes. The most common concern of the governments of all nations affected by Covid-19 is the intolerable need to screen and test large numbers of patients for possible Sars-Cov-2 infections. As a result, most of them face significant bottlenecks in the supply of diagnostic kits to test for the virus. Diagnostic virology companies have been under immense pressure so as to provide reliable test kits and also the demand for the in vitro or point-of-care testing capabilities in the laboratories in various countries is also increasing. However, with the introduction of automated SARS-CoV-2 test systems, the diagnosis increases its capacity to carry out such tests considerably. However, currently, only a few companies are focused on developing rapid immunoassay tests for Covid-19 diagnosis.

Influencing Trend: A Shift in Focus from Centralized Laboratories to Decentralized Point-Of-Care Testing

An Upsurge in Validating and Developing Rapid POC Immunodiagnostic Tests to Facilitate Decentralized Testing

Growing Trend of Incorporation of Artificial Intelligence (AI) in the COVID-19 Tests for Rapid and Efficient Diagnosis

Challenges: Shortage of Medical Professionals That Have Sufficient Knowledge Regarding the Use of Diagnostic Kits for COVID-19

Opportunities: Growth in Funding For Research on Coronavirus Diagnostics

Increasing Application of Molecular Diagnostic Technologies in Pharmacogenetics and Point-Of-Care Testing

The Rise in Integration of Novel Technologies and Software Solutions with COVID-19 Testing

Market Growth Drivers: The Increasing Global Prevalence of COVID-19

Unavailability of Specific Medicine or a Vaccine for the Coronavirus Disease

An Increase in the Need for Developing Diagnostic Tests Owing to the Global Conditions

The Increased Demand for Rapid Immunoassay Tests for Disease Diagnosis

The Global Coronavirus Diagnostics segments and Market Data Break Down by Type (Molecular, Serology, Antigen-Based), Product Used (Instruments, Reagents & Kits), Infection Type (HCoV-229E, HCoV-OC43, SARS-CoV, HKU1-CoV, MERS-CoV), End-Users (Hospitals, Public Health Labs, Private or Commercial Labs, Physician Labs, Diagnostic Centers and Clinics, Research Institutes, Others), Sample Type (Nasopharyngeal (NP) Swab, Oropharyngeal (OP) Swab, Nasal Swab), Mode of Diagnosis (Point-of-Care (POC), Non-Point-of-Care (Non-PoC))

Presented By

AMA Research & Media LLP

0 notes

research--blog · 2 years ago

Text

In-vitro Diagnostics (IVD) Reagents Market Worth $77.6 billion by 2027, Growing at a CAGR of 7% From 2020, Says Meticulous Research®

According to a new market research report “In-Vitro Diagnostic Reagents Market by Type (Oligonucleotide, Antibodies, Nucleic Acid Probe), Technology (Immunoassay, Hematology, Microbiology), Use (Research, Analyte Specific Reagent), End User (IVD Manufacturer, Clinical Laboratory) – Forecast to 2027”, published by Meticulous Research®, the IVD reagents market is expected to grow at a CAGR of 7% from 2020 to reach USD 77.6 billion by 2027.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5110

The epidemiological burden of infectious diseases across the globe has increased in the past few years. During past few decades, various infections such as Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), Ebola, chikungunya, avian flu, swine flu, and Zika are the majorly occurred emerging infections. The recent outbreak of the coronavirus (COVID-19) disease is an example of the same. Testing is one of the greatest tools in understanding and managing the pandemics. Apart from this, the advances in protein-engineering technologies, such as mass spectrometry; advances in molecular genetics; and progress in production technologies are some of the key drivers of the IVD reagents market. This has urged drug developers to exploit the functional characteristics of desired proteins by maintaining or enhancing product safety or efficacy. The fastest-growing class of therapeutic proteins is an antibody that includes bispecific mAbs and multispecific fusion proteins, and mAbs conjugated with small molecule drugs designed for the treatment of cancers, immune disorders, infections, and other diseases. According to a research article published in F1000Research (an innovative open access publishing platform), the recent developments in protein purification technologies and expression systems have increased the production of therapeutic peptides while maintaining product safety or efficacy or both at the same time. Due to this, the number of therapeutic peptides approvals has grown significantly over the past few years.

Further, government initiatives for the development of personalized medicines, which include monoclonal antibodies as its major part, boosted the production of antibodies. Therefore, the increasing demand for therapeutic proteins and personalized medicine and their subsequent increase in approvals is expected to create significant opportunities for the players operating in the IVD reagents market.

Impact of COVID-19 on the IVD Reagents Market

The COVID-19 pandemic has adversely hit many economies around the globe. In this global pandemic, although many dedicated healthcare professionals work tirelessly on the frontlines to fight against this crisis, it is equally important to minimize the spread of disease by preparing kits for early diagnosis. Thus, the outbreak of the COVID-19 pandemic has created immense opportunities for the IVD reagents market as testing has provided one of the greatest solutions in managing the pandemic. In response to the pandemic and shortages of laboratory-based molecular testing capacity and reagents, multiple diagnostic test manufacturers have developed and begun selling various assays & kits which are prepared by using the IVD reagents.

Speak to our Analysts to Understand the Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5110

Thus, this increase in the launch of newer diagnostic kits will result in the increased adoption of IVD reagents for the kits or the assay development, thereby providing lucrative opportunities for the IVD reagents manufactures in the upcoming years.

The overall IVD reagents market is mainly segmented by type (oligonucleotide, antibodies, nucleic acid probe), technology (immunoassay, hematology, microbiology), use (research, analyte specific reagent), end user (IVD manufacturer, clinical laboratory), and geography. The study also evaluates industry competitors and analyzes their market share at a global and regional level.

On the basis of technology, the immunoassay/immunochemistry segment accounted for the largest share of the overall IVD reagents market in 2020. However, the molecular diagnostics segment is expected to grow at the fastest CAGR during the forecast period due to factors such as the high prevalence of infectious diseases, rising awareness of personalized medicine and companion diagnostics, and advancements in molecular techniques. Further, the rising focus of market players on the development of diagnostic NGS kits and reagents and rising penetration of cutting-edge clinical laboratory technologies are also responsible for the fastest growth of the segment.

Base on the type of reagent, the antibodies segment accounted for the largest share of the overall market in 2020, owing to the widespread application of antibodies in medicine for the purpose of research, diagnosis, drug & IVD development, and disease treatment; increasing proteomics & genomics-based research and funding for R&D; and rising need for disease specific biomarkers.

On the basis of use of the IVD reagent, the clinical use segment commanded the largest share of the overall IVD reagent market in 2020. Rising number of initiatives undertaken by manufacturers for the development of advanced IVD reagents for clinical applications, ongoing clinical trials, and exemption from the investigational device (IDE) requirements are some of the factors driving the growth of this segment.

Based on the end user, reference laboratories accounted for the largest share of the overall IVD reagents market in 2020, due to factors such as the exponential increase in the number of accredited clinical laboratories, growing R&D activities in labs, presence of skilled professionals & well-equipped systems, and outbreak of COVID-19.

Quick Buy – IVD Reagent Market Research Report: https://www.meticulousresearch.com/Checkout/29579204

The report also includes extensive assessment of the product portfolio, geographic analysis, and key strategic developments adopted by leading market participants in the industry over the past 3 years. The IVD reagents market has witnessed number of collaborations and expansions in recent years.

Geographically, emerging economies like Asia-Pacific and Latin America are expected to offer significant growth opportunities for IVD reagents manufactures due to the rising demand for antibodies & oligonucleotides, increasing funding for R&D, rising healthcare expenditure, and ongoing developments in the healthcare infrastructure. Countries such as China, India, Brazil, and Mexico have been significant contributors to revenue generation for various stakeholders in the overall IVD reagents market. This is mainly due to the increasing number of research institutes, clinical & diagnostic laboratories, and pharmaceutical & biopharmaceutical industries. In addition, rising public & private funding for R&D and rising contract research in these countries are further supporting the growth of the IVD reagents market in these countries.

Some of the key players operating in the overall IVD reagents market are Becton, Dickinson and Company (U.S.), Merck KGaA (Germany), Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), LGC Biosearch Technologies (U.K.), BioLegend, Inc. (U.S.), InBios International, Inc. (U.S.), LakePharma, Inc. (U.S.), Bioline (U.K.), Abcam plc (U.K.), The Binding Site Group Ltd.(U.K.), SDIX, LLC (U.S.), DIACLONE SAS (France), Bio-Techne Corporation (U.S.), Agilent Technologies, Inc. (U.S.), Hologic Inc. (U.S.), Bio-Synthesis Inc. (U.S.), RayBiotech, Inc. (U.S.), and Sino Biological Inc. (China), among others.

Scope of the Report:

IVD Reagents Market, by Technology

Immunoassay/Immunochemistry

Biochemistry/Clinical Chemistry

Molecular Diagnostics

Microbiology

Hematology

Coagulation/Hemostatis

Other technologies

Other Technologies comprises of hybridization and loop-mediated isothermal amplification

IVD Reagents Market, by Type

Antibodies

Oligonucleotides

Nucleic Acid Probes

Purified Proteins or Peptides

Other reagents

Other reagents comprises of blocking agents, detergents, surfactants, wetting agents, buffers, stabilizers, purified water, dyes, standards & controls, enzymes, cell culture reagents, anti-coagulants

IVD Reagents Market, by Use

Research Use

Analyte Specific Reagents

Clinical Use

IVD Reagents Market, by End User

IVD Manufacturers

Reference Laboratories

Academic & Research Institutes

Hospital Laboratories

IVD Reagents Market, by Geography

North America

U.S.

Canada

Europe

Germany

France

Italy

U.K.

Spain

Rest of Europe

Asia-Pacific (APAC)

Japan

China

India

Rest of Asia Pacific

Latin America

Middle East & Africa

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5110

0 notes

businesspr · 2 years ago

Text

Coronavirus Testing Kits Market Focus on Past-Current Size, Shares, Trends, Segment and Forecast 2031

Coronavirus Testing Kits Market report is venues where customers and sellers come together to exchange products and services available. The fundamental concepts underpinning Coronavirus Testing Kits market 2023-2031 transactions include supply and demand, market structure, elasticity, and equilibrium state. Supply and demand determine the cost, while Coronavirus Testing Kits market structure…

View On WordPress

0 notes

mysticalfungalaxy · 2 years ago

Text

Covid-19 Diagnostics Market Booming Worldwide Opportunity, Competitive Analysis, Future Prospects 2032 | FMI

The Covid-19 Diagnostics Market is expected to exceed US$ 204.51 billion by 2032, growing at a 7.7% CAGR.

With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis on Covid-19 Diagnostics market.

Gain complete access to the report @ https://www.futuremarketinsights.com/reports/covid-19-diagnostics-market

FMI offers insights into the market data on over 5000+ drugs for more than 100 countries, which further aids the research on current and upcoming market scenario for the Covid-19 Diagnostics market. Our expert researchers and analysts for healthcare tracks the data of established players as well as new entrants in medical industry to provide an unbiased analysis for a sound and financial decision.

Over the past decade, healthcare sector has been expanding remarkably, following the advent of artificial Intelligence and the Internet of Things integrated medical devices. Advancement in technology has created impressive scope within the medical sector for diagnostics and therapeutics.

The report offers extensive data sets validating key trends impacting growth in the Covid-19 Diagnostics market. It offers insights into strategies adopted by the key players rise and address the concerns that will challenge the growth of Covid-19 Diagnostics market. With our extensive research and information about the past, current and future market scenario, the Covid-19 Diagnostics market report will help and identify the concerns, for a smooth-sail of the small & medium as well as large enterprises.

Coronavirus screening typically involve testing for the presence of the SARS-CoV-2 virus or its antibodies in a person's body.

Competitive Analysis

By Prominent Market Players

Veredus Laboratories

Thermo Fisher Scientific, Inc.

Quidel Corporation

Perkin Elmer, Inc.

Neuberg Diagnostics

Mylab Discovery Solutions Pvt Ltd.

Luminex Corporation

Laboratory Corporation of America Holdings

Hologic Inc.

Others

Get a Full PDF Sample Copy of the Latest Reports @ https://www.futuremarketinsights.com/reports/sample/rep-gb-12366

Covid-19 Diagnostics Market: Segmentation

Product Type

Instruments

Test Kits

Reagents and Consumables

Sample Type

Oropharyngeal & Nasopharyngeal Swabs

Blood

Urine

Others

Technology

PCR

ELISA

POC

Why Future Market Insights?

Comprehensive analysis on evolving purchase pattern across different geographies

Detailed insights of market segments and sub-segments for historical as well as forecast period

A competitive analysis of prominent players and emerging players in the Covid-19 Diagnostics market

Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

#Covid-19 Diagnostics Market #healthcare

0 notes

impossibledeanmakerwombat · 2 years ago

Text

Virology Specimen Collection Market: Worldwide Industry Analysis and New Market Opportunities Explored to 2032

According to a recent virology specimen collection market report by Future Market Insights (FMI), the motor monitoring market is anticipated to advance at a phenomenal CAGR of -0.5% over the forecast period 2022-2032. The market for virology specimen collection was valued at US$ 5.6 billion globally in 2021, and it is anticipated to grow at a negative CAGR of -0.5% from 2022 to 2032.

Additionally, the rising prevalence of viral infections like SARS-CoV-2, AIDS, flu, EBOLA, Zika virus, and STDs boosts the demand for virology specimen collection.

The Zika virus and Babesia outbreaks, alongside announcements for their inclusion in virology specimen collection tests, indicate the need for innovation in virology specimen collection technologies, consumables, laboratory testing and instruments. Other countries have also undertaken initiatives to check for new and emerging diseases.

Request for a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14266

The high cost of technologies and collection kits and usage of flow sensitivity screening are the major factors hampering the growth of the virology specimen collection market.

Some emerging markets such as India, the Middle East, and Africa offer promising virology specimen collection opportunities for players in the industry due to their increasing disposable incomes and improving healthcare infrastructure.

The comparatively high cost of laboratory testing has boosted the increasing use of older and less practical tests, for example, first-generation ELISA.

The test has been used in various parts of the world despite its limitation.

The high costs of the virology specimen collection products serve as the critical factor curtailing the growth impetus in the market.

There is a crucial requirement to reduce the costs of these products to create demand for virology specimen collection. Otherwise, it is estimated to hinder the virology specimen collection growth even in upcoming years.

During the diagnostics investigations, different microbiology specimen collection mediums are recommended to stabilize specimens for the detection of viruses and bacteria.

Thus, based on these factors, the virology swab sample market is likely to experience innumerable growth avenues in the forthcoming years.

It is expected to have a digital future of public health, and there comes a crucial requirement to align the international strategies for evaluation and regulation.

There is high competition among the virology specimen collection market players.

Only major companies can afford high-capital investments and the cost of R&D and manufacturing. That prevents new entrants from entering the virology specimen collection market.

Key Takeaways:

North America is anticipated to be at the forefront of the virology specimen collection market future trends, which can be attributed to the increasing adoption of NAT and technological advancements such as portable diagnostics.

The bacterial specimen collection segment is projected to lead the virology collection market trend by product type. The high prevalence of tuberculosis (TB) is one of the significant factors contributing to the share of the segment.

Diagnostic applications are expected to account for a significant portion of the virology specimen collection market size due to a spike in the number of FDA-approved specimen collection kits, transport of viral specimen, and virology swab sample for clinical applications.

By end use, the hospitals and clinics segment is anticipated to generate the most revenue, owing to an uptick in patients with respiratory viruses and bacterial infections.

The Asia Pacific market for bacterial and virology sample collection is expected to grow at a rapid pace because of extensive coronavirus testing in Asian countries.

By technology, the segment of the nasopharyngeal sample is estimated to hold sway on account of rapid detection of transmissible transfusion infections (TTIs) and the rising prevalence of HPV-related cancers and human papillomavirus (HPV).

Ask from Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-14266

“Virology specimen collection tests emphasize the need for virology specimen collection technology innovation and adoption, consumables, and instruments. This is projected to drive the demand for the virology specimen collection market further.” opines an FMI analyst.

Competitive Landscape:

A few notable virology specimen collection market players include Puritan Medical Products Co. (UK), Trinity Biotech (Ireland), Dickinson and Company (US), Thermo Fisher Scientific Inc. (US), Vircell S.L. (Spain), Becton, Quidel Corporation (US), Titan Biotech Ltd. (India), Diasorin SA (Italy), Copan Italia S.P.A (Italy), Hardy Diagnostics (US).

These firms and companies are partnering & collaborating with several domestic and international players as a part of the emerging trends in the viral specimen collection market.

Henkel AG & Co. KGaA of Germany tied up with Origin of California to leverage the latter’s expertise in performing robust mechanical testing at its California facility. Henkel also contributed expertise and technology to developing 3D printed nasopharyngeal swabs for COVID-19 testing and several other recent developments in the virology specimen collection market.

Under a USD 6.0 million contract with Inflammatix Inc., the US HHS supported the development of the host-response testing technology. The company is working on three diagnostic tests that will provide quick results on whether the infection is bacterial or viral. This enables clinicians to make better-informed, earlier treatment decisions. Such initiatives are also at the heart of the companies’ strategy to expand earlier diagnosis.

Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-14266

Key Segments By Product Type:

Blood Collection Kits

Specimen Collection Tubes

Viral Transport Media

Swabs

By Sample:

Blood Samples

Nasopharyngeal Samples

Throat Samples

Nasal Samples

Cervical Samples

Oral Samples

Other Samples

0 notes

yeomanhealthusa · 2 years ago

Text

How To Buy PURITAN MEDICAL FOAM SWABS

For the samples described below, same-day shipping is possible. Verify that this specific swab is appropriate for your purpose. Everything might have a much higher stock.

All in-stock items come with a promise of same-day delivery. Every item that is in stock comes with free domestic shipping. Additionally offered by FedEx is cross-border international shipment. FedEx calculates all of the shipping and import taxes for you.

Wellness

Yeoman Health & Wellness carries high-quality products from brands like Puritan Medical, SmartCrutch, Midwest Filters, York Nordic, and many more. Products with free standard delivery that are in stock are often sent out the same day. Click on the logo of a specific manufacturer to read more about it.

Modern medical swabs under the smartCRUTCH brand have a revolutionary, height-adjustable forearm and are available in a range of sizes and hues.

For more than a century, Puritan has produced high-quality swabs and other wood products. The leading supplier of viral testing supplies and equipment on the market, Puritan, is working around the clock to address the pressing needs of the testing and medical communities.

York Nordic: Walking poles made by York Nordic are stylish and practical, making them appropriate for walkers of all ages. The poles have been used in educational settings and medical research endeavours all around the nation.

Yeoman: Yeoman carries every single-use medical equipment made by the Puritans, including swabs, kits, and other gadgets. We provide same-day shipping for products that are in stock.

Delivery is free on all domestic purchases made in the US (including Alaska and Hawaii).

All overseas shipments are handled through FedEx Crossborder. When an item is in stock, it is delivered the same day to the shipping facility. FedEx automatically manages all taxes and shipping charges for you.

Backorders are available for all Puritan products that are currently out of stock.

Oenology and Genetics

Yeoman carries all single-use medical applicators from the Puritan brand, including swabs, kits, and other items. If an item is in stock, we might be able to mail it that day.

All overseas shipments are handled through FedEx Crossborder. When an item is in stock, it is delivered the same day to the shipping facility. FedEx will decide the shipping fees, taxes, and other charges when you place an order with them.

Backorders are available for all Puritan products that are currently out of stock. Within 24 hours, each backorder will get confirmation of the delivery date and lead time (M-F). A Puritan's swab is necessary for a reliable coronavirus test. The flocked, round foam, and spun polyester swabs are three different Puritan product variations that the Centers for Disease Control and Prevention (CDC) supports. A viral collection and storage system called UniTranz-RT® is produced by Puritan. Our kits are made to make sure that clinical specimens get where they need to go without a hitch when on-site testing is not an option. UniTranz-RT® complies with the CDC's provisional guidelines for the collection, processing, and testing of specimens. For collecting samples from the nose and oral cavities, flock foam swabs are superior than conventional swabs.

#puritan sterile swabs

0 notes

market-insider · 2 years ago

Text

U.S. Veterinarians Market Positively Impacted By Tests And Veterinary Telehealth Services During COVID-19

The U.S. veterinarians market size is poised to reach USD 23.3 billion by 2030, expanding at a CAGR of 8.7% during the forecast period, as per a new report by Grand View Research, Inc. The rising cases of zoonotic and chronic diseases, increasing animal health expenditure, and growing pet health concerns are the key factors driving the market. An estimated total of around 132,138 professionals were actively involved in the veterinary profession in the U.S. Approximately 57% of the U.S. veterinarians were employed in private practices in 2020. This number is estimated to increase in the coming years, owing to a rise in demand for veterinary services.

Although the COVID-19 pandemic presented several challenges to the animal health industry, it highlighted the need to secure the health of pets as well as food animals. With containment measures such as lockdowns & movement restrictions, manufacturing companies and veterinary service providers were significantly affected. Animal disease surveillance and reporting activities, such as outbreak investigation & disease reporting, were also disrupted due to logistical issues. This included restrictions & constraints on access to farms & transport of samples and veterinary equipment & PPE kits during the pandemic.

Gain deeper insights on the market and receive your free copy with TOC now @: U.S. Veterinarians Market Report

However, companies manufacturing products or providing services that helped ease the pandemic burden, such as COVID-19 tests and veterinary telehealth services, were positively impacted. Veterinary visits too plunged due to the pandemic. However, the numbers soon recovered as veterinary services were recognized as an essential service. The U.S. government also announced several financial stimulus packages, flexible norms, and guidelines to ensure business continuity.

The Coronavirus Response and Relief Supplemental Appropriations Act & the Coronavirus Aid, Relief, and Economic Security (CARES) Act came into force to provide rapid & direct economic assistance to workers, families, & small businesses, and to preserve jobs in the U.S. Among other provisions, this included the Paycheck Protection Program to assist small businesses. C4, or the fourth COVID-19 relief bill, passed by the U.S. Congress in December 2020, included additional relief measures. Key provisions of C4 included a simplified loan waiver of up to USD 150,000, applicable to most veterinary practices.

With the growing number of pet parents in the U.S. and adoption of pet insurance, demand for animal health services is rising amongst people. In 2020, about 3.45 million pets had insurance coverage across North America, as per the North American Pet Health Insurance Association. Out of these, 3.1 million pets were insured in the U.S. alone. The highest percentage of insured pets were found to reside in California, New York, and Florida.

Dogs were the most frequently insured pets as compared to cats.Among the many available career paths, a notable number of U.S. veterinarians pursue teaching and/or research careers as faculty, thus contributing to the significant revenue share of the academics segment. New graduates are also inclined to enter internships and residencies at private veterinary practices or veterinary medicine colleges.

#U.S. Veterinarians Market Size & Share #U.S. Veterinarians Market Latest Trends #U.S. Veterinarians Market Growth Forecast #COVID-19 Impacts On U.S. Veterinarians Market #U.S. Veterinarians Market Revenue Value

0 notes

kenresearchcompany · 2 years ago

Text

Global Immunoassays Market is expected to record a positive CAGR of ~6% during the forecast period 2022-2028: Ken Research

Immunoassays are bioanalytical techniques that use the precision of an antigen-antibody reaction to detect and quantify analytes in biological samples such as urine, blood, saliva, tissues, and cells. Clinical diagnostics, drug discovery, environmental monitoring, biopharmaceutical analysis, drug monitoring, and food testing are all common applications for such techniques. In addition, they generally exhibit quick and precise outcomes, allowing a clinician to diagnose a variety of diseases such as diabetes, cancer, and heart disease accurately.

The Global Immunoassays Market is expected to record a positive CAGR of ~6% during the forecast period (2022-2028) and reach a revenue of ~US$ 60 Bn by 2028, due to the rising prevalence of chronic and infectious diseases. The ongoing Covid-19 pandemic has accelerated the use of immune-diagnostics assays for correct diagnosis and containment of the Covid-19 pandemic. In addition, immunoassay tests are highlighted as an important diagnostic method as they enable reliable and affordable detection of viruses and bacteria. Such tests are used to detect both acute and chronic diseases.

For more information, request a free sample @ https://www.kenresearch.com/sample-report.php?Frmdetails=NTkyNDkz

The rising prevalence of chronic, and infectious diseases, including COVID-19, HIV/AIDS, dengue, foodborne disease, and other diseases is one of the major factors propelling the immunoassays market growth.

In addition, the cost-effectiveness and higher efficiency of immunoassay tests also make a significant contribution to their growth.

For instance, the WHO Pan American Health Organization (PAHO) reported 21,41,240 dengue cases in the Americas, including 10,53,420 confirmed cases and 927 associated deaths, as of August 2022. In addition, Brazil (19,10,657), Peru (57,469), Colombia (38,844), Nicaragua (37,369), and Ecuador have reported the most cases (12,645) during the same period.

In addition, according to the study conducted in 2021 by Food Security Cluster, an Italian non-profit organization that outlines food availability, access, and utilization issues, more than 600 million individuals (one in ten) globally, become ill with the foodborne disease each year, and 420,000 die.

Technical challenges with immunoassay kits/reagents and instruments are likely to impede the market growth.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak had been proclaimed a public health emergency in late January 2020, medical professionals and scientists experienced the necessity for extensive and rapid testing of individuals to implement measures to contain the virus's spread. Additionally, real-time PCR (RTPCR) tests and antibody/antigen tests have erupted as vital tools for the global healthcare system in managing the outbreak.

Key Trends by Market Segment

By Product Type: Reagents & Kits hold the largest share of the Global Immunoassays Market in 2021.

Reagents/kits are a preferable type of product for immunoassay testing as they offer a quick, simple, and cost-effective method of detection with accuracy and specificity considerably better (in some cases) than other methods.

The global outbreak of Covid-19 has prompted governments to impose critical measures to prevent its spread, which focus primarily on accurate and prompt identification of virus-infected individuals using the most precise and sensitive method available, notably real-time reverse transcriptase PCR (RT-PCR). This has raised the global demand for detection kits.

For more information, request a free sample @ https://www.kenresearch.com/ask-customization.php?Frmdetails=NTkyNDkz

By Application: The infectious disease segment held the largest market share in 2021.

The rising global prevalence rate of infectious diseases such as HIV/AIDS, malaria, dengue fever, influenza, and Covid-19 is one of the major factors driving the demand for immunoassays tests for infectious diseases.

For instance, according to the world health organization (WHO), influenza leads to around 3 to 5 million serious cases and 250,000 to 500,000 deaths worldwide every year.

The growing number of cancer cases worldwide is also a significant contributor to the expansion of the immunoassay market during the forecast period.

For instance, according to the American Cancer Society, cancer continues to be the second leading cause of death in the U.S., after cardiovascular disease. In 2022, the U.S. is expected to see 1.9 million new cancer cases and 609,360 cancer deaths, for a total of 1,670 deaths per day.

By Technology: The Enzyme Immunoassays (EIA)/Enzyme-linked immunosorbent assays (ELISA) technology segment dominated the market for immunoassays in 2021.

This technology's accuracy and ability to provide quick results is a major driving factor. In addition, ELISA's simple procedure, high specificity and sensitivity, cost-effectiveness, and high efficiency are all contributing factors to its growth.

Furthermore, the use of ELISA/EIA for antigen/antibody detection is among the most commonly available diagnostic tools, and it is extensively used for diagnosing swine influenza as well.

According to the National Library of Medicine (NLM), operated by the U.S. federal government, ELISA, indirect fluorescence antibody (IFA), and virus neutralizing assays are used to detect porcine parainfluenza virus type-1 (PPIV-1) antibody in swine serum.

By End User: The Hospitals & Clinics segment account for the majority share of the Global Immunoassays Market in 2021.

The continuous development in the healthcare industry across countries has raised the requirement for hospitals with advanced techniques and facilities.

The growing number of infectious diseases tested during the assessments and processing of body fluids, particularly following the worldwide explosion of the Covid-19 pandemic, are other major factors influencing the demand for immunoassays tests in hospitals and clinics.

By Geography: North America accounts for the largest share among all Regions within the total Immunoassays market in 2021.

Increased technological adoption in diagnostic techniques, extensive research initiatives, and increasing government funding for point-of-care testing and regulatory science activities across the healthcare industry are all contributing factors to the growth of Immunoassays in North America.

For instance, in November 2021, the U.S. Department of Health and Human Services (HHS) announced a USD 650 million investment to enhance manufacturing capacity for fast, high-quality diagnostic testing via rapid point-of-care molecular tests that help in the detection of influenza, respiratory syncytial virus (RSV), and a cluster of respiratory viruses.

In October 2020, the National Institutes of Health announced the third round of contract awards for the intensity and manufacturing of new COVID-19 testing technologies in collaborative efforts with the Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services.

Additionally, the six new rapid acceleration of diagnostics (RADx) initiative contracts comprise USD 98.35 million for point-of-care and other novel testing techniques that provide modes of sample collection, processing, and output. Inclusion with smart devices, digital processing that can be deployed to COVID-19 hot spots, and test results readily accessible in minutes are among the advancements in such new techniques.

The Asia Pacific region is expected to grow at the fastest CAGR during the forecasted period 2022-2028, owing to the government's increased emphasis on improving healthcare infrastructure, the adoption of innovative laboratory techniques and procedures, such as blotting technique, and gel electrophoresis for quicker and more efficient examination and diagnosis of infectious and chronic diseases, and growing preference for diagnostic reagents.

To more regional trends, Ask for a Customization @ https://www.kenresearch.com/sample-report.php?Frmdetails=NTkyNDkz

Competitive Landscape

The Global Immunoassays market is highly competitive with ~500 players which include globally diversified players, regional players as well as a large number of country-niche players each with their niche bioanalytical setting such as clinical diagnostics, biopharmaceutical analysis, environmental monitoring, security, and food testing, and others, for end-users. The immunoassays market's growth is heavily reliant on detection technologies and advancements in testing equipment and instruments.

Country-Niche players constitute about ~75% of the competitors, while regional players constitute about ~20%. Some of the major players in the market include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Becton, Dickinson and Company (BD), Bio-Rad Laboratories, Inc., Siemens Healthineers, Thermo Fisher Scientific, Danaher Corporation, PerkinElmer, Quidel Corporation, Ortho Clinical Diagnostics Holdings, Sysmex Corporation, DiaSorin S.p.A. and among others.

Recent Developments Related to Major Players and Organizations

In February 2022, Siemens Healthineers, a German healthcare company, launched Enhanced Liver Fibrosis (ELF) Test in the U.S., offering broad clinical access to the nonsurgical diagnostic tool. In addition, the Food and Drug Administration (FDA) granted De Novo marketing authorization for the test.

In July 2021, Roche, a Swiss pharmaceutical company, announced the launch of its new Elecsys Epstein-Barr virus (EBV) immunoassay panel, which includes the Elecsys EBV IgM, EBV VCA IgG, and EBV EBNA IgG immunoassays and detects Epstein-Barr virus antibodies at various infection stages.

In April 2021, DiaSorin, an Italian Biotechnology company, launched its new immunodiagnostic Point-of-Care (POC) reader 'LIAISON IQ' and the 'LIAISON Quick Detect Covid TrimericS Ab' test. The LIAISON IQ's test detects specific IgG antibodies against SARS-CoV-2 Spike Protein in human blood capillaries from a throat swab in 10 minutes.

In February 2021, Thermo Fisher Scientific Inc., a U.S.-based manufacturer of analytical laboratory instruments, announced a partnership with Mindray, a Chinese medical device company, to make two clinical chemistry analyzers available to customers in the United States (U.S.) and Canada for drug of abuse testing.

In April 2020, Bio-Rad Laboratories, a U.S.-based manufacturer of specialized technological products for the life science research and clinical diagnostics markets, announced the release of a blood-based immunoassay kit to detect antibodies to the coronavirus SARS-CoV-2, the virus associated with COVID-19.

Conclusion

The Global Immunoassays Market is forecasted to continue steady growth that is witnessed since 2017. The market is primarily driven by the rising prevalence of chronic, and infectious diseases, including COVID-19. Though the market is highly competitive with over ~500 participants, few global players control the dominant share and regional players also hold a significant share.

Note: This is an upcoming/planned report, so the figures quoted here for market size estimate, forecast, growth, segment share and competitive landscape are based on initial findings and might vary slightly in the actual report. Also, any required customizations can be covered to the best feasible extent for Pre-booking clients and report delivered within maximum 2 working weeks.

Market Taxonomy

The Global Immunoassays Market Size, Segments, Outlook, and Revenue Forecast 2022-2028 is segmented by Product Types, Application, Technology, and End-User. In addition, the report also covers the market size for each of the five regions' immunoassays markets. The revenue used to size and forecast the market for each segment is USD billion.

By Type

Reagents & Kits

Analyzers/Instruments

Software & Services

By Application

Cardiology

Oncology

Autoimmune Diseases

Infectious Diseases

Others

By Technology

Radio immunoassay (RIA)

Enzyme Immunoassays (EIA) or Enzyme-linked immunosorbent assays (ELISA)

Fluoro Immunoassay (FIA)

Chemiluminescence Immunoassay (CLIA)

Others

By End User

Hospital & Clinics

Clinical Laboratories

Pharmaceuticals & Biotech Companies

Blood Banks

Academic Research Centers

Others

By Geography

North America (U.S., Canada, Mexico)

Europe (Germany, UK, France, Italy, Spain, Rest of Europe)

Asia Pacific (China, Japan, India, Australia, South Korea, Rest of Asia Pacific)

Latin America, Middle East and Africa

0 notes

perrysblogs · 2 years ago

Link

0 notes

sanpdr1994 · 2 years ago

Text

Covid-19 Diagnostics Market 2022 Analysis by Global Key Players | Industry Share, Size, Revenue, Competition and Forecast to 2032

Strong focus on ‘test & trace’, and growing clamor for mass testing will continue to drive demand for Covid-19 diagnostics in 2020 and beyond, according to a new research by ESOMAR-certified firm Future Market Insights (FMI).

The study provides a long-term outlook on the Covid-19 testing kits market, providing a likely scenario until 2030. Although successful vaccines are likely to be developed by 2021, a growing body of research is suggesting that Covid-19 will become endemic, as is the case with other coronaviruses. An exponential rise in the number of Covid-19 patients across the globe followed by requirements of rapid diagnostics will continue to drive demand.

As of now, research is being conducted regarding diagnostics as well as treatments. Diagnostics comprise PCR-based tests and serological or antibody testing. Antibody tests are best-suited for checking for herd immunities in recovered patients, whereas PCR tests serve the purpose of early detection of coronavirus. The healthcare industry is emphasizing on development of immunotherapy, vaccines, cell-based and antiviral therapies. As of May 2020, there were 124 vaccines and 205 diverse therapies under development. The core areas of research are inclusive of protein-based vaccines, drug re-purposes, antibodies, cell-based therapies, non-replicating viral vectors, and RNA-based vaccines.

For More Information : https://www.futuremarketinsights.com/reports/covid-19-diagnostics-market

Key Takeaways from FMI’s Covid-19 Diagnostics Market Study

Molecular assay holds the largest share right now and the trend is expected to continue till the end of 2020. This could be attributed to the fact that molecular assays have been looked upon as a gold standard to detect novel viral infections

Diagnostic labs contributed to more than 60% of total market share in 2020’s first quarter

Key Challenges for Market Players & Researchers

Right now, the challenges faced include lack of information regarding the virus, like genetic information, biologics, duration of immunity in the recovered patients. Certain treatment options that are expected to be potential game changers include ACE-Mab by Sorrento Therapeutics, HCQ (Hydroxychloroquine and chloroquine), Remdesivir antiviral by Gilead Sciences, and Canakinumab (Ilaris) by Novartis.

Moreover, options like cell-based therapies that involve natural killer cells or Mesenchymal stem cells and plasma therapies are on the verge of providing personalized treatment options.

Key Participant Insights

The key participants are focusing on acceleration of production as well as new product approval phase. For example – Novacyt Group, in Mar 2020, received EUA for 2-hour Covid-19 test. Also, in Apr 2020, CE approval was received by Abbott for IgG serology blood test for Covid-19.

The other players in the market include Veredus Laboratories, Thermo Fisher Scientific, Inc., Quidel Corporation, Perkin Elmer, Inc., Neuberg Diagnostics, Mylab Discovery Solutions Pvt Ltd., Luminex Corporation, Laboratory Corporation of America Holdings, Hologic Inc., Danaher, Cepheid, bioMérieux SA, Altona Diagnostics GmbH, ALDATU BIOSCIENCES, ADT Biotech Sdn Bhd, and 1drop Inc.

#Covid-19 Diagnostics Market #Covid-19 Diagnostics Market Size #Covid-19 Diagnostics Market Growth

0 notes

kritikapatil · 2 years ago